NB02(POSELTINIB) Monotherapy in R/R Non-Hodgkin's Lymphoma

Summary

This trial is an open-label, multicenter, monotherapy, dose-escalation, phase 1 clinical trial to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary anti-tumor activity of NB02 (posseltinib) in patients with relapsed/refractory NHL including FL, MCL and MZL

Timeline

Start

2025-12-02

Primary completion

2026-12-31

Completion

2027-12-31

Drugs

Indications